Despite significant advancements in the production of platelet products, storage, and
transfusion, transfusion refractoriness remains a significant clinical problem, affecting up to …

Platelet transfusion refractoriness due HLA alloimmunization presents a significant medical
problem, particularly among multiply transfused patients with hematologic malignancies and …

Many patients worldwide receive platelet components (PCs) through the transfusion of
diverse types of blood components. PC transfusions are essential for the treatment of central …

BACKGROUND Platelet transfusions can induce alloimmunization against HLA antigens.
The use of pathogen‐reduced platelet concentrates (PCs) was suggested to reduce HLA …

Reports from both adult and paediatric populations indicate that approximately two-thirds of
platelet transfusions are used prophylactically to prevent bleeding, while the remaining one …

Background Platelet transfusions can be associated with adverse reactions, such as febrile
non-haemolytic transfusion reaction (FNHTR). It has been suggested that damage …

Transfusion has become extremely safe but can still be associated with adverse reactions.
Some adverse reactions can be mitigated by applying measures to donor selection, the …

Immune-mediated platelet refractoriness (PR) remains a significant problem in the setting of
platelet transfusion and is predominantly caused by the presence of alloantibodies directed …

Pathogen inactivation or reduction technologies for platelet components have been
proposed to secure the microbial safety of this component, and particularly the microbial …

Alloimmunisation to platelet antigens is not uncommon; a large number of females, having
had pregnancies, developed antibodies to Human Leukocyte Antigen (HLA) moieties …